Treatment Strategy and Safety of Eribulin in Advanced Breast Cancer

This study sought to investigate the efficacy and safety of eribulin in advanced breast cancer patients. Eighteen patients with advanced breast cancer were retrospectively included. The previous use of taxanes, and the use of eribulin in subsequent treatment was reviewed. Progression- free survival（PFS）and the efficacy of eribulin, influencing factors, and adverse reactions were analysed. For patients who were previously treated with taxanes were more resistant, subsequent eribulin treatment chemotherapy PFS was generally for two months. However, for patients who chose eribulin combined with anlotinib for the latter-line regimen, PFS reached for five months, and these patients were in continuous remission. Among the 18 patients, 17 patients (94.4%) had different degrees of bone marrow suppression. Patients who have not been treated with taxanes or who have been treated with taxanes for a long response time, experience better effects when eribulin was used as subsequent treatment. Eribulin combined with anlotinib is the preferred combination therapy. Key Words: Breast cancer, Eribulin, Efficacy, Safety.